JP2017095457A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017095457A5 JP2017095457A5 JP2016222861A JP2016222861A JP2017095457A5 JP 2017095457 A5 JP2017095457 A5 JP 2017095457A5 JP 2016222861 A JP2016222861 A JP 2016222861A JP 2016222861 A JP2016222861 A JP 2016222861A JP 2017095457 A5 JP2017095457 A5 JP 2017095457A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antibody
- drug
- drug conjugate
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000611 antibody drug conjugate Substances 0.000 claims 8
- 108091008116 antibody drug conjugates Proteins 0.000 claims 8
- 108090001123 antibodies Proteins 0.000 claims 6
- 102000004965 antibodies Human genes 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010017758 Gastric cancer Diseases 0.000 claims 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 2
- 210000003494 Hepatocytes Anatomy 0.000 claims 2
- 206010024324 Leukaemias Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010025310 Other lymphomas Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 2
- 206010034299 Penile cancer Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000007452 Plasmacytoma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 206010038038 Rectal cancer Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 206010061934 Salivary gland cancer Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 206010041823 Squamous cell carcinoma Diseases 0.000 claims 2
- 206010046766 Uterine cancer Diseases 0.000 claims 2
- 206010047741 Vulval cancer Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 201000011231 colorectal cancer Diseases 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 125000005647 linker group Chemical group 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 201000001275 rectum cancer Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 1
Claims (10)
- 次式のいずれかで示されるリンカー及び薬物と、抗HER2抗体と、が結合した抗体−薬物コンジュゲート:
-(Succinimid-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2CH2-O-CH2-C(=O)-(NH-DX)、及び
-(Succinimid-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2-O-CH2CH2-O-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-(NH-DX)。
(式中、
-(Succinimid-3-yl-N)-は次式:
で示される構造であり、このものの3位で抗HER2抗体とチオエーテル結合によって結合し、1位の窒素原子上でこれを含むリンカー構造内のメチレン基と結合し、
-(NH-DX)は次式:
で示される、1位のアミノ基の窒素原子が結合部位となっている基を示す。) - 前記抗HER2抗体が、配列番号1においてアミノ酸番号1乃至449に記載のアミノ酸配列からなる重鎖及び配列番号2においてアミノ酸番号1乃至214に記載のアミノ酸配列からなる軽鎖を含んでなる、請求項1記載の抗体−薬物コンジュゲート。
- 前記抗HER2抗体が、配列番号1に記載のアミノ酸配列からなる重鎖及び配列番号2に記載のアミノ酸配列からなる軽鎖を含んでなる、請求項1記載の抗体−薬物コンジュゲート。
- 選択された薬物−リンカー構造の1抗体あたりの平均結合数が2から8個の範囲である請求項1〜3のいずれか一項に記載の抗体−薬物コンジュゲート。
- 選択された薬物−リンカー構造の1抗体あたりの平均結合数が3から8個の範囲である請求項1〜3のいずれか一項に記載の抗体−薬物コンジュゲート。
- 請求項1〜5のいずれか一項に記載の抗体−薬物コンジュゲート、その塩、又はそれらの水和物を含有する医薬。
- 請求項1〜5のいずれか一項に記載の抗体−薬物コンジュゲート、その塩、又はそれらの水和物を含有する抗腫瘍薬及び/又は抗癌薬。
- 肺癌、尿路上皮癌、大腸癌、前立腺癌、卵巣癌、膵癌、乳癌、膀胱癌、胃癌、胃腸間質腫瘍、子宮頸癌、食道癌、扁平上皮癌、腹膜の癌、肝臓癌、肝細胞癌、結腸癌、直腸癌、結腸直腸癌、子宮内膜癌、子宮癌、唾液腺癌、腎臓癌、外陰部癌、甲状腺癌、陰茎癌、白血病、悪性リンパ腫、形質細胞腫、骨髄腫、又は肉腫に適用するための請求項7記載の抗腫瘍薬及び/又は抗癌薬。
- 請求項1〜5のいずれか一項に記載の抗体−薬物コンジュゲート、その塩、又はそれらの水和物を活性成分とし、薬学的に許容される製剤成分とを含有する医薬組成物。
- 肺癌、尿路上皮癌、大腸癌、前立腺癌、卵巣癌、膵癌、乳癌、膀胱癌、胃癌、胃腸間質腫瘍、子宮頸癌、食道癌、扁平上皮癌、腹膜の癌、肝臓癌、肝細胞癌、結腸癌、直腸癌、結腸直腸癌、子宮内膜癌、子宮癌、唾液腺癌、腎臓癌、外陰部癌、甲状腺癌、陰茎癌、白血病、悪性リンパ腫、形質細胞腫、骨髄腫、又は肉腫に適用するための請求項9記載の医薬組成物。
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014017777 | 2014-01-31 | ||
JP2014017777 | 2014-01-31 | ||
JP2014168944 | 2014-08-22 | ||
JP2014168944 | 2014-08-22 | ||
JP2014227886 | 2014-11-10 | ||
JP2014227886 | 2014-11-10 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016166850A Division JP6046301B1 (ja) | 2014-01-31 | 2016-08-29 | 抗her2抗体−薬物コンジュゲート |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017003826A Division JP6105183B1 (ja) | 2014-01-31 | 2017-01-13 | 抗her2抗体−薬物コンジュゲート |
JP2019002311A Division JP6665325B2 (ja) | 2014-01-31 | 2019-01-10 | 抗her2抗体−薬物コンジュゲート |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2017095457A JP2017095457A (ja) | 2017-06-01 |
JP2017095457A5 true JP2017095457A5 (ja) | 2018-03-01 |
JP6466895B2 JP6466895B2 (ja) | 2019-02-06 |
Family
ID=53756672
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015542503A Active JP5998289B2 (ja) | 2014-01-31 | 2015-01-28 | 抗her2抗体−薬物コンジュゲート |
JP2016166850A Active JP6046301B1 (ja) | 2014-01-31 | 2016-08-29 | 抗her2抗体−薬物コンジュゲート |
JP2016222861A Active JP6466895B2 (ja) | 2014-01-31 | 2016-11-16 | 抗her2抗体−薬物コンジュゲート |
JP2017003826A Active JP6105183B1 (ja) | 2014-01-31 | 2017-01-13 | 抗her2抗体−薬物コンジュゲート |
JP2019002311A Active JP6665325B2 (ja) | 2014-01-31 | 2019-01-10 | 抗her2抗体−薬物コンジュゲート |
JP2020025886A Active JP6914380B2 (ja) | 2014-01-31 | 2020-02-19 | 抗her2抗体−薬物コンジュゲート |
JP2021115436A Active JP7146031B2 (ja) | 2014-01-31 | 2021-07-13 | 抗her2抗体-薬物コンジュゲート |
JP2022149242A Active JP7467557B2 (ja) | 2014-01-31 | 2022-09-20 | 抗her2抗体-薬物コンジュゲート |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015542503A Active JP5998289B2 (ja) | 2014-01-31 | 2015-01-28 | 抗her2抗体−薬物コンジュゲート |
JP2016166850A Active JP6046301B1 (ja) | 2014-01-31 | 2016-08-29 | 抗her2抗体−薬物コンジュゲート |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017003826A Active JP6105183B1 (ja) | 2014-01-31 | 2017-01-13 | 抗her2抗体−薬物コンジュゲート |
JP2019002311A Active JP6665325B2 (ja) | 2014-01-31 | 2019-01-10 | 抗her2抗体−薬物コンジュゲート |
JP2020025886A Active JP6914380B2 (ja) | 2014-01-31 | 2020-02-19 | 抗her2抗体−薬物コンジュゲート |
JP2021115436A Active JP7146031B2 (ja) | 2014-01-31 | 2021-07-13 | 抗her2抗体-薬物コンジュゲート |
JP2022149242A Active JP7467557B2 (ja) | 2014-01-31 | 2022-09-20 | 抗her2抗体-薬物コンジュゲート |
Country Status (29)
Country | Link |
---|---|
US (4) | US10155821B2 (ja) |
EP (4) | EP3973995A1 (ja) |
JP (8) | JP5998289B2 (ja) |
KR (12) | KR102190548B1 (ja) |
CN (2) | CN105829346B (ja) |
AU (3) | AU2015212265B2 (ja) |
BR (1) | BR112016013482B1 (ja) |
CA (1) | CA2928794C (ja) |
CY (2) | CY1121573T1 (ja) |
DK (2) | DK3466976T3 (ja) |
ES (2) | ES2895254T3 (ja) |
FR (1) | FR21C1030I2 (ja) |
HR (2) | HRP20211848T1 (ja) |
HU (3) | HUE057464T2 (ja) |
IL (4) | IL278891B2 (ja) |
LT (3) | LT3101032T (ja) |
MX (2) | MX2016006498A (ja) |
NL (1) | NL301117I2 (ja) |
NO (1) | NO2021027I1 (ja) |
NZ (1) | NZ719202A (ja) |
PH (1) | PH12016500904B1 (ja) |
PL (2) | PL3466976T3 (ja) |
PT (2) | PT3466976T (ja) |
RS (2) | RS62618B1 (ja) |
SG (2) | SG10201800210TA (ja) |
SI (2) | SI3101032T1 (ja) |
TW (9) | TWI796243B (ja) |
WO (1) | WO2015115091A1 (ja) |
ZA (1) | ZA201602802B (ja) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2907824T1 (en) | 2012-10-11 | 2018-06-29 | Daiichi Sankyo Company, Limited | THE HEALTHY KJUBIER OF THE PROTITEL |
KR102088169B1 (ko) * | 2013-12-25 | 2020-03-12 | 다이이찌 산쿄 가부시키가이샤 | 항 trop2 항체-약물 컨쥬게이트 |
KR102190548B1 (ko) * | 2014-01-31 | 2020-12-14 | 다이이찌 산쿄 가부시키가이샤 | 항-her2 항체-약물 접합체 |
ES2754348T3 (es) * | 2014-04-10 | 2020-04-17 | Daiichi Sankyo Co Ltd | Conjugado de (anticuerpo anti-HER2)-fármaco |
WO2015195925A1 (en) | 2014-06-18 | 2015-12-23 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates and methods of using same |
TWI695011B (zh) | 2014-06-18 | 2020-06-01 | 美商梅爾莎納醫療公司 | 抗her2表位之單株抗體及其使用之方法 |
BR112017027690A2 (pt) | 2015-06-29 | 2018-10-09 | Daiichi Sankyo Co Ltd | método para produção de uma composição de conjugado anticorpo-fármaco, e, composição de conjugado anticorpo-fármaco |
CN109789211A (zh) * | 2016-10-07 | 2019-05-21 | 第一三共株式会社 | 基于抗her2抗体-药物偶联物施予的耐性癌的治疗 |
EP3552626A4 (en) | 2016-12-12 | 2020-06-10 | Daiichi Sankyo Company, Limited | ASSOCIATION OF AN ANTIBODY DRUG CONJUGATE AND AN IMMUNE CONTROL POINT INHIBITOR |
KR20190120764A (ko) * | 2017-02-28 | 2019-10-24 | 갓코 호진 긴키 다이가쿠 | 항 her3 항체-약물 콘주게이트 투여에 의한 egfr-tki 저항성의 비소세포 폐암의 치료 방법 |
CN108653746B (zh) * | 2017-03-29 | 2021-04-27 | 北京键凯科技股份有限公司 | 一种多载药点、高载药配基药物偶联物 |
MA49987A (fr) | 2017-08-23 | 2020-07-01 | Daiichi Sankyo Co Ltd | Préparation de conjugué anticorps-médicament et lyophilisation associée |
CN111065621B (zh) | 2017-08-31 | 2024-01-26 | 第一三共株式会社 | 制备抗体-药物缀合物的新方法 |
SG11202000997YA (en) * | 2017-08-31 | 2020-03-30 | Daiichi Sankyo Co Ltd | Improved method for producing antibody-drug conjugate |
EP4249002A3 (en) | 2018-05-18 | 2023-11-22 | Daiichi Sankyo Co., Ltd. | Anti-muc1- exatecan antibody-drug conjugate |
KR20210014660A (ko) | 2018-05-28 | 2021-02-09 | 다이이찌 산쿄 가부시키가이샤 | 항 her2 항체-약물 콘쥬게이트 투여에 의한 her2 변이암의 치료 |
KR20210038904A (ko) | 2018-07-25 | 2021-04-08 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘쥬게이트의 효과적인 제조 방법 |
EP3831853A4 (en) * | 2018-07-27 | 2022-06-01 | Daiichi Sankyo Company, Limited | ANTIBODY-DRUG CONJUGATE PROTEIN-RECOGNIZING DRUG UNIT |
AU2019315177A1 (en) * | 2018-07-31 | 2021-02-25 | Daiichi Sankyo Company, Limited | Treatment of metastatic brain tumor by administration of antibody-drug conjugate |
CN110790840A (zh) * | 2018-08-01 | 2020-02-14 | 三生国健药业(上海)股份有限公司 | 结合人her2的抗体、其制备方法和用途 |
BR112021001750A2 (pt) * | 2018-08-06 | 2021-04-27 | Daiichi Sankyo Company, Limited | composição farmacêutica |
JP7481255B2 (ja) | 2018-08-23 | 2024-05-10 | 第一三共株式会社 | 抗体薬物複合体の感受性マーカー |
US20210353764A1 (en) | 2018-09-26 | 2021-11-18 | Jiangsu Hengrui Medicine Co., Ltd. | Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof |
BR112021004829A2 (pt) | 2018-09-30 | 2021-06-08 | Jiangsu Hengrui Medicine Co., Ltd. | conjugado de anticorpo anti-b7h3-análogo de exatecano e uso medicinal do mesmo |
CN113271942A (zh) * | 2018-12-11 | 2021-08-17 | 第一三共株式会社 | 抗体-药物缀合物与parp抑制剂的组合 |
AU2019407426A1 (en) * | 2018-12-21 | 2021-07-22 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
CN109824759A (zh) * | 2019-03-08 | 2019-05-31 | 联宁(苏州)生物制药有限公司 | 一种用于抗体药物偶联物的药物-连接子mc-mmaf的制备方法及其中间体 |
HUE060364T2 (hu) | 2019-03-29 | 2023-02-28 | Medimmune Ltd | Vegyületek és konjugátumaik |
CN111686259B (zh) * | 2019-05-26 | 2023-08-08 | 成都百利多特生物药业有限责任公司 | 一种含sn38的抗体药物偶联物 |
CA3144790A1 (en) * | 2019-06-28 | 2020-12-30 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Antibody-drug conjugate, intermediate thereof, preparation method therefor and application thereof |
CN112125915A (zh) * | 2019-09-18 | 2020-12-25 | 四川百利药业有限责任公司 | 一种喜树碱衍生物及其偶联物 |
CA3159770A1 (en) | 2019-11-15 | 2021-05-20 | Seagen Inc. | Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate |
BR112022011032A2 (pt) | 2019-12-12 | 2022-08-16 | Jiangsu Hengrui Medicine Co | Conjugado de anticorpo-fármaco anti-claudina e uso farmacêutico do mesmo |
CA3163130A1 (en) | 2019-12-16 | 2021-06-24 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-cea antibody-exatecan analog conjugate and pharmaceutical use thereof |
CN114846021B (zh) | 2020-01-22 | 2024-06-14 | 江苏恒瑞医药股份有限公司 | 抗trop-2抗体-依喜替康类似物偶联物及其医药用途 |
CN115103691A (zh) * | 2020-03-25 | 2022-09-23 | 江苏恒瑞医药股份有限公司 | 一种含抗体药物偶联物的药物组合物及其用途 |
CN115298186A (zh) | 2020-03-25 | 2022-11-04 | 江苏恒瑞医药股份有限公司 | 抗psma抗体-依喜替康类似物偶联物及其医药用途 |
JP2023521956A (ja) | 2020-03-25 | 2023-05-26 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 抗体薬物複合体の調製方法 |
JP7486615B2 (ja) * | 2020-06-12 | 2024-05-17 | アピカル モレキュラー バイオテック カンパニー リミテッド | 非アルコール性脂肪性肝疾患および非アルコール性脂肪性肝炎を治療するためのプテロスチルベンアミノ酸含有炭酸塩の新規類縁体 |
WO2021260583A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and dna-pk inhibitor |
TW202216207A (zh) * | 2020-06-24 | 2022-05-01 | 英商阿斯特捷利康英國股份有限公司 | 抗體-藥物結合物及cdk9抑制劑之組合 |
JP2023539715A (ja) * | 2020-06-24 | 2023-09-19 | アストラゼネカ ユーケー リミテッド | 抗体-薬物コンジュゲートとatm阻害剤との組合わせ |
TW202216208A (zh) * | 2020-06-24 | 2022-05-01 | 英商阿斯特捷利康英國股份有限公司 | 抗體-藥物結合物及atr抑制劑之組合 |
WO2021260582A1 (en) * | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and aurora b inhibitor |
CN115515644A (zh) * | 2020-06-28 | 2022-12-23 | 昆山新蕴达生物科技有限公司 | 一种抗体-药物偶联物,其制备方法及应用 |
US20230293714A1 (en) | 2020-07-20 | 2023-09-21 | Daiichi Sankyo Company, Limited | Combination of anti-her2 antibody-drug conjugate with her dimerization inhibitor |
CN115702008A (zh) * | 2020-08-13 | 2023-02-14 | 正大天晴药业集团股份有限公司 | 抗体药物偶联物 |
JP2023545359A (ja) | 2020-09-12 | 2023-10-30 | アストラゼネカ・ユーケイ・リミテッド | 抗her2抗体-薬物複合体治療のためのスコアリング方法 |
WO2022056696A1 (zh) * | 2020-09-15 | 2022-03-24 | 四川百利药业有限责任公司 | 一种喜树碱类药物及其抗体偶联物 |
CN116239601B (zh) * | 2020-09-30 | 2023-10-13 | 映恩生物制药(苏州)有限公司 | 一种抗肿瘤化合物及其制备方法和应用 |
IL301921A (en) | 2020-10-09 | 2023-06-01 | Daiichi Sankyo Co Ltd | Combining an antibody-drug conjugate and a selective 1PARP inhibitor |
AU2021361938A1 (en) * | 2020-10-12 | 2023-05-25 | Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Deuterated camptothecin derivative and antibody-drug conjugate thereof |
WO2022078260A1 (zh) * | 2020-10-12 | 2022-04-21 | 四川百利药业有限责任公司 | 一种喜树碱类衍生物及其配体-药物偶联物 |
KR20230106645A (ko) | 2020-11-11 | 2023-07-13 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트와 항 SIRPα 항체의 조합 |
US20230398230A1 (en) | 2020-11-12 | 2023-12-14 | Daiichi Sankyo Company, Limited | Treatment of mesothelioma by administration of anti-b7-h3 antibody-drug conjugate |
CN112535738B (zh) * | 2020-12-04 | 2022-09-09 | 中国科学技术大学 | 奥沙利铂偶联物及其制备方法和应用 |
TW202245844A (zh) * | 2021-01-13 | 2022-12-01 | 紀念斯隆凱特琳癌症中心 | 抗dll3抗體-藥物結合物 |
CN116888123A (zh) * | 2021-02-09 | 2023-10-13 | 微境生物医药科技(上海)有限公司 | 用于adc制备的喜树碱衍生物 |
WO2022194257A1 (zh) * | 2021-03-17 | 2022-09-22 | 江苏恒瑞医药股份有限公司 | 一种喜树碱衍生物的制备方法 |
CN116867789A (zh) * | 2021-03-31 | 2023-10-10 | 上海复旦张江生物医药股份有限公司 | 一种伊喜替康衍生物的制备方法及其中间体 |
IL308246A (en) * | 2021-05-07 | 2024-01-01 | Alx Oncology Inc | Exataxane derivatives and antibody-drug conjugates thereof |
CN113402584A (zh) * | 2021-07-06 | 2021-09-17 | 联宁(苏州)生物制药有限公司 | 一种抗体偶联药物连接子的中间体lnd1067-l1的合成方法 |
US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
US11814394B2 (en) | 2021-11-16 | 2023-11-14 | Genequantum Healthcare (Suzhou) Co., Ltd. | Exatecan derivatives, linker-payloads, and conjugates and thereof |
WO2023089527A1 (en) | 2021-11-18 | 2023-05-25 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and parp1 selective inhibitor |
TW202333800A (zh) * | 2021-12-28 | 2023-09-01 | 英商阿斯特捷利康英國股份有限公司 | 抗體-藥物結合物及rasg12c抑制劑之組合 |
CA3240724A1 (en) | 2021-12-28 | 2023-07-06 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and atr inhibitor |
WO2023175483A1 (en) | 2022-03-16 | 2023-09-21 | Astrazeneca Uk Limited | A scoring method for an anti-trop2 antibody‑drug conjugate therapy |
TW202400140A (zh) | 2022-04-27 | 2024-01-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物與ezh1及/或ezh2抑制劑之組合 |
TW202400650A (zh) * | 2022-05-11 | 2024-01-01 | 日商第一三共股份有限公司 | 抗體與cd47抑制劑之組合 |
WO2024015830A1 (en) | 2022-07-12 | 2024-01-18 | Cytomx Therapeutics, Inc. | Epcam immunoconjugates and uses thereof |
WO2024023750A1 (en) | 2022-07-28 | 2024-02-01 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and bispecific checkpoint inhibitor |
CN117024438A (zh) * | 2022-07-29 | 2023-11-10 | 杭州爱科瑞思生物医药有限公司 | 依沙替康衍生物及其应用 |
US20240116945A1 (en) * | 2022-09-02 | 2024-04-11 | Merck Sharp & Dohme Llc | Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof |
Family Cites Families (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
ATE185601T1 (de) | 1990-07-10 | 1999-10-15 | Cambridge Antibody Tech | Verfahren zur herstellung von spezifischen bindungspaargliedern |
US5637770A (en) | 1991-01-16 | 1997-06-10 | Daiichi Pharmaceutical Co., Ltd. | Hexa-cyclic compound |
JP3008226B2 (ja) | 1991-01-16 | 2000-02-14 | 第一製薬株式会社 | 六環性化合物 |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
DK0605522T3 (da) | 1991-09-23 | 2000-01-17 | Medical Res Council | Fremgangsmåde til fremstilling af humaniserede antistoffer |
ATE463573T1 (de) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
EP0656941B1 (en) | 1992-03-24 | 2005-06-01 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
JP3359955B2 (ja) | 1992-07-16 | 2002-12-24 | 第一製薬株式会社 | 抗腫瘍剤 |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
EP0731842A1 (en) | 1993-12-03 | 1996-09-18 | Medical Research Council | Recombinant binding proteins and peptides |
JPH08337584A (ja) | 1995-04-10 | 1996-12-24 | Dai Ichi Seiyaku Co Ltd | 縮合六環式アミノ化合物、これを含有する医薬及びその製法 |
US6504029B1 (en) | 1995-04-10 | 2003-01-07 | Daiichi Pharmaceutical Co., Ltd. | Condensed-hexacyclic compounds and a process therefor |
SG50747A1 (en) | 1995-08-02 | 1998-07-20 | Tanabe Seiyaku Co | Comptothecin derivatives |
JPH1095802A (ja) | 1995-12-28 | 1998-04-14 | Tanabe Seiyaku Co Ltd | カンプトテシン誘導体 |
CA2192725C (en) | 1995-12-28 | 2004-04-20 | Kenji Tsujihara | Camptothecin derivatives |
TW527183B (en) | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
TW409058B (en) | 1996-06-06 | 2000-10-21 | Daiichi Seiyaku Co | Method for preparation of a drug complex |
JPH1171280A (ja) | 1997-06-26 | 1999-03-16 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
JPH1192405A (ja) | 1997-09-19 | 1999-04-06 | Dai Ichi Seiyaku Co Ltd | 薬物複合体 |
DE69942021D1 (de) | 1998-04-20 | 2010-04-01 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
JP4560210B2 (ja) * | 1998-05-22 | 2010-10-13 | 第一三共株式会社 | 薬物複合体 |
CN1661044A (zh) | 1998-10-30 | 2005-08-31 | 第一制药株式会社 | Dds化合物及其测定方法 |
DK2270149T3 (en) | 1999-04-09 | 2016-05-09 | Kyowa Hakko Kirin Co Ltd | PROCEDURE TO CONTROL THE ACTIVITY OF IMMUNOLOGICAL FUNCTIONAL MOLECULE. |
KR100850389B1 (ko) | 1999-06-25 | 2008-08-04 | 제넨테크, 인크. | 인간화 항-ErbB2 항체 및 항-ErbB2 항체를 사용한치료 방법 |
BRPI0017590B8 (pt) | 1999-06-25 | 2021-05-25 | Genentech Inc | conjugado de maitansinoide - anticorpo anti-erbb, e formulação farmacêutica |
JP2002060351A (ja) | 2000-03-22 | 2002-02-26 | Dai Ichi Seiyaku Co Ltd | 水酸基を有する薬物を含むdds化合物 |
IL153505A0 (en) | 2000-06-29 | 2003-07-06 | Daiichi Seiyaku Co | Dds compound and process for the preparation thereof |
CN1556712A (zh) | 2000-07-13 | 2004-12-22 | ��һ��������ҩ��ʽ���� | 含dds化合物的药用组合物 |
CN102311986B (zh) | 2000-10-06 | 2015-08-19 | 协和发酵麒麟株式会社 | 产生抗体组合物的细胞 |
TWI313609B (en) | 2001-08-21 | 2009-08-21 | Mitsubishi Tanabe Pharma Corp | Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor |
KR100573565B1 (ko) | 2001-08-29 | 2006-04-25 | 주식회사 포스코 | 요철부가 형성된 실린더 링과 이 실린더 링이 결합된 맨드릴 |
WO2003038043A2 (en) | 2001-11-01 | 2003-05-08 | Uab Research Foundation | Combinations of dr5 antibody and other therapeutic agents |
JP2005511627A (ja) | 2001-11-20 | 2005-04-28 | シアトル ジェネティクス,インコーポレーテッド | 抗cd30抗体を使用する免疫学的疾患の治療 |
US8877901B2 (en) | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
US9745380B2 (en) | 2002-03-01 | 2017-08-29 | Immunomedics, Inc. | RS7 antibodies |
US20050276812A1 (en) | 2004-06-01 | 2005-12-15 | Genentech, Inc. | Antibody-drug conjugates and methods |
EP1572242B1 (en) | 2002-12-13 | 2014-04-16 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
US20040202666A1 (en) | 2003-01-24 | 2004-10-14 | Immunomedics, Inc. | Anti-cancer anthracycline drug-antibody conjugates |
WO2005084390A2 (en) | 2004-03-02 | 2005-09-15 | Seattle Genetics, Inc. | Partially loaded antibodies and methods of their conjugation |
JP4806680B2 (ja) | 2004-05-19 | 2011-11-02 | メダレックス インコーポレイテッド | 自己犠牲リンカー及び薬剤複合体 |
KR20120068807A (ko) * | 2004-07-22 | 2012-06-27 | 제넨테크, 인크. | Her2 항체 조성물 |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
EP1817341A2 (en) | 2004-11-29 | 2007-08-15 | Seattle Genetics, Inc. | Engineered antibodies and immunoconjugates |
KR20170134771A (ko) | 2005-01-21 | 2017-12-06 | 제넨테크, 인크. | Her 항체의 고정 용량 투여법 |
DE102005009084A1 (de) | 2005-02-28 | 2006-08-31 | Ktb Tumorforschungsgesellschaft Mbh | Proteinbindende Anthrazyklin-Peptid-Derivate und diese enthaltende Arzneimittel |
DE102005009099A1 (de) | 2005-02-28 | 2006-08-31 | Ktb Tumorforschungsgesellschaft Mbh | Proteinbindende Camptothecin-Peptid-Derivate und diese enthaltende Arzneimittel |
US7833979B2 (en) | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
JP2006316040A (ja) * | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(登録商標)補助療法 |
WO2007100385A2 (en) | 2005-10-31 | 2007-09-07 | Genentech, Inc. | Macrocyclic depsipeptide antibody-drug conjugates and methods |
US20080131428A1 (en) | 2006-02-24 | 2008-06-05 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
DK2446904T3 (en) * | 2006-05-30 | 2015-07-27 | Genentech Inc | The anti-CD22 antibodies, immunoconjugates and their uses thereof |
UA95958C2 (en) | 2006-05-30 | 2011-09-26 | Дженентек, Инк. | Antibody that binds to cd22, immunoconjugates and uses therefor |
ITMI20061473A1 (it) | 2006-07-26 | 2008-01-27 | Indena Spa | Derivati della camptotecina ad attivita antitumorale |
PL2254571T3 (pl) * | 2008-03-18 | 2015-11-30 | Genentech Inc | Kombinacje koniugatu przeciwciała anty-HER2-lek i środki chemioterapeutyczne oraz sposoby zastosowania |
PL2281006T3 (pl) * | 2008-04-30 | 2018-01-31 | Immunogen Inc | Środki łączące i ich zastosowania |
AU2009246516B2 (en) * | 2008-05-13 | 2015-03-05 | Genentech, Inc. | Analysis of antibody drug conjugates by bead-based affinity capture and mass spectrometry |
BRPI0921586A2 (pt) | 2008-11-18 | 2019-09-24 | Merrimack Pharmaceuticals Inc | articuladores de albumina de soro humana e conjugados destes |
DK3912643T3 (da) | 2009-02-13 | 2022-10-17 | Immunomedics Inc | Immunokonjugater med en intracellulært-spaltelig binding |
JP5705836B2 (ja) | 2009-05-29 | 2015-04-22 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Her2を発現する胃癌患者のher2シグナル伝達のためのモジュレーター |
KR20120104158A (ko) * | 2009-07-22 | 2012-09-20 | 엔즌 파마슈티칼스, 인코포레이티드 | 7-에틸-10-히드록시캠토테신의 다분지형 중합 컨쥬게이트와 her2 수용체 길항제를 병용하여 her2 양성 암을 치료하는 방법 |
WO2011022474A2 (en) | 2009-08-18 | 2011-02-24 | Baker Hughes Incorporated | Method of forming polystalline diamond elements, polycrystalline diamond elements, and earth boring tools carrying such polycrystalline diamond elements |
CA2775350A1 (en) | 2009-09-24 | 2011-03-31 | Seattle Genetics, Inc. | Dr5 ligand drug conjugates |
WO2011068845A1 (en) | 2009-12-02 | 2011-06-09 | Immunomedics, Inc. | Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy |
BR112012028704A2 (pt) | 2010-05-13 | 2019-09-24 | Univ Indiana Res & Tech Corp | composto de glugagon da superfamília de peptídeos exibindo atividade do receptor com hormônio nuclear, pró fármaco, dímero ou multímero, composição farmacêutica que o compreendem e método de administração do mesmo. |
NZ702053A (en) | 2010-05-17 | 2016-01-29 | Livtech Inc | Anti-human trop-2 antibody having antitumor activity in vivo |
CN105797168A (zh) | 2010-05-18 | 2016-07-27 | 天蓝制药公司 | 用于治疗自身免疫性疾病或其它疾病的组合物和方法 |
EP2594589A1 (en) | 2010-06-10 | 2013-05-22 | Sapporo Medical University | ANTI-Trop-2 ANTIBODY |
BR112013000951A2 (pt) * | 2010-07-12 | 2016-05-17 | Covx Technologies Ireland Ltd | conjungados de anticorpo multifuncionais |
WO2012019024A2 (en) | 2010-08-04 | 2012-02-09 | Immunogen, Inc. | Her3-binding molecules and immunoconjugates thereof |
JP6014596B2 (ja) | 2010-11-09 | 2016-10-25 | メディミューン,エルエルシー | 均一コンジュゲーションのための抗体足場 |
WO2012074757A1 (en) | 2010-11-17 | 2012-06-07 | Genentech, Inc. | Alaninyl maytansinol antibody conjugates |
EP2776470A2 (en) | 2011-11-11 | 2014-09-17 | Rinat Neuroscience Corporation | Antibodies specific for trop-2 and their uses |
US9427464B2 (en) | 2011-11-22 | 2016-08-30 | Chiome Bioscience Inc. | Anti-human TROP-2 antibody having an antitumor activity in vivo |
SG11201403085PA (en) | 2011-12-14 | 2014-10-30 | Seattle Genetics Inc | Fgfr antibody drug conjugates (adcs) and the use thereof |
US20130280282A1 (en) | 2012-04-24 | 2013-10-24 | Daiichi Sankyo Co., Ltd. | Dr5 ligand drug conjugates |
KR20150023729A (ko) | 2012-06-14 | 2015-03-05 | 암브룩스, 인코포레이티드 | 핵 수용체 리간드 폴리펩티드에 접합된 항-psma 항체 |
SI2907824T1 (en) | 2012-10-11 | 2018-06-29 | Daiichi Sankyo Company, Limited | THE HEALTHY KJUBIER OF THE PROTITEL |
US9872924B2 (en) | 2012-10-19 | 2018-01-23 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate produced by binding through linker having hydrophilic structure |
JP6262768B2 (ja) * | 2013-01-03 | 2018-01-17 | セルトリオン, インク. | 抗体−リンカー−薬物結合体、その製造方法およびそれを含む抗癌剤組成物 |
KR102088169B1 (ko) | 2013-12-25 | 2020-03-12 | 다이이찌 산쿄 가부시키가이샤 | 항 trop2 항체-약물 컨쥬게이트 |
KR102190548B1 (ko) * | 2014-01-31 | 2020-12-14 | 다이이찌 산쿄 가부시키가이샤 | 항-her2 항체-약물 접합체 |
KR20240008415A (ko) | 2014-04-10 | 2024-01-18 | 다이이찌 산쿄 가부시키가이샤 | 항her3 항체-약물 콘주게이트 |
-
2015
- 2015-01-28 KR KR1020187031594A patent/KR102190548B1/ko active IP Right Grant
- 2015-01-28 PT PT18204861T patent/PT3466976T/pt unknown
- 2015-01-28 HU HUE18204861A patent/HUE057464T2/hu unknown
- 2015-01-28 HR HRP20211848TT patent/HRP20211848T1/hr unknown
- 2015-01-28 WO PCT/JP2015/000355 patent/WO2015115091A1/ja active Application Filing
- 2015-01-28 KR KR1020227038845A patent/KR102510128B1/ko active IP Right Grant
- 2015-01-28 SG SG10201800210TA patent/SG10201800210TA/en unknown
- 2015-01-28 KR KR1020167015961A patent/KR101916553B1/ko active IP Right Grant
- 2015-01-28 KR KR1020237008409A patent/KR102557062B1/ko active IP Right Grant
- 2015-01-28 IL IL278891A patent/IL278891B2/en unknown
- 2015-01-28 KR KR1020227022459A patent/KR102465042B1/ko active IP Right Grant
- 2015-01-28 DK DK18204861.1T patent/DK3466976T3/da active
- 2015-01-28 EP EP21187152.0A patent/EP3973995A1/en not_active Withdrawn
- 2015-01-28 CN CN201580003121.4A patent/CN105829346B/zh active Active
- 2015-01-28 JP JP2015542503A patent/JP5998289B2/ja active Active
- 2015-01-28 ES ES18204861T patent/ES2895254T3/es active Active
- 2015-01-28 KR KR1020217021044A patent/KR102314913B1/ko active IP Right Grant
- 2015-01-28 EP EP15743738.5A patent/EP3101032B1/en active Active
- 2015-01-28 KR KR1020237040108A patent/KR20230162159A/ko active Search and Examination
- 2015-01-28 LT LTEP15743738.5T patent/LT3101032T/lt unknown
- 2015-01-28 DK DK15743738.5T patent/DK3101032T3/en active
- 2015-01-28 PT PT15743738T patent/PT3101032T/pt unknown
- 2015-01-28 NZ NZ719202A patent/NZ719202A/en unknown
- 2015-01-28 CA CA2928794A patent/CA2928794C/en active Active
- 2015-01-28 KR KR1020237024073A patent/KR102606930B1/ko active IP Right Grant
- 2015-01-28 SI SI201530587T patent/SI3101032T1/sl unknown
- 2015-01-28 KR KR1020217032820A patent/KR102362920B1/ko active IP Right Grant
- 2015-01-28 KR KR1020207035147A patent/KR102238848B1/ko active IP Right Grant
- 2015-01-28 PL PL18204861T patent/PL3466976T3/pl unknown
- 2015-01-28 CN CN201910768778.XA patent/CN110464847B/zh active Active
- 2015-01-28 EP EP22198821.5A patent/EP4212552A1/en active Pending
- 2015-01-28 EP EP18204861.1A patent/EP3466976B1/en active Active
- 2015-01-28 RS RS20211465A patent/RS62618B1/sr unknown
- 2015-01-28 RS RS20190280A patent/RS58415B1/sr unknown
- 2015-01-28 AU AU2015212265A patent/AU2015212265B2/en active Active
- 2015-01-28 SI SI201531748T patent/SI3466976T1/sl unknown
- 2015-01-28 SG SG11201603960XA patent/SG11201603960XA/en unknown
- 2015-01-28 IL IL310627A patent/IL310627A/en unknown
- 2015-01-28 PL PL15743738T patent/PL3101032T3/pl unknown
- 2015-01-28 BR BR112016013482-6A patent/BR112016013482B1/pt active IP Right Grant
- 2015-01-28 KR KR1020227004389A patent/KR102417312B1/ko active IP Right Grant
- 2015-01-28 ES ES15743738T patent/ES2727351T3/es active Active
- 2015-01-28 HU HUE15743738 patent/HUE044389T2/hu unknown
- 2015-01-28 KR KR1020217009854A patent/KR102275925B1/ko active IP Right Grant
- 2015-01-28 LT LTEP18204861.1T patent/LT3466976T/lt unknown
- 2015-01-28 MX MX2016006498A patent/MX2016006498A/es active IP Right Grant
- 2015-01-30 TW TW111122222A patent/TWI796243B/zh active
- 2015-01-30 TW TW107116039A patent/TWI661839B/zh active
- 2015-01-30 TW TW108114649A patent/TWI722422B/zh active
- 2015-01-30 TW TW112104986A patent/TW202322817A/zh unknown
- 2015-01-30 TW TW104103127A patent/TWI627967B/zh active
- 2015-01-30 TW TW111122224A patent/TWI796245B/zh active
- 2015-01-30 TW TW111122223A patent/TWI796244B/zh active
- 2015-01-30 TW TW111122225A patent/TWI796246B/zh active
- 2015-01-30 TW TW110104664A patent/TWI789700B/zh active
-
2016
- 2016-04-21 IL IL245252A patent/IL245252B/en active IP Right Grant
- 2016-04-22 ZA ZA2016/02802A patent/ZA201602802B/en unknown
- 2016-05-16 PH PH12016500904A patent/PH12016500904B1/en unknown
- 2016-05-18 MX MX2020010682A patent/MX2020010682A/es unknown
- 2016-07-28 US US15/221,851 patent/US10155821B2/en active Active
- 2016-08-29 JP JP2016166850A patent/JP6046301B1/ja active Active
- 2016-11-16 JP JP2016222861A patent/JP6466895B2/ja active Active
-
2017
- 2017-01-13 JP JP2017003826A patent/JP6105183B1/ja active Active
-
2018
- 2018-09-13 US US16/130,615 patent/US11795236B2/en active Active
-
2019
- 2019-01-10 JP JP2019002311A patent/JP6665325B2/ja active Active
- 2019-03-05 HR HRP20190431TT patent/HRP20190431T1/hr unknown
- 2019-04-11 CY CY20191100406T patent/CY1121573T1/el unknown
- 2019-05-21 IL IL266790A patent/IL266790A/en active IP Right Grant
-
2020
- 2020-01-29 AU AU2020200596A patent/AU2020200596B2/en active Active
- 2020-02-19 JP JP2020025886A patent/JP6914380B2/ja active Active
- 2020-08-19 US US16/997,613 patent/US11584800B2/en active Active
-
2021
- 2021-07-06 HU HUS2100025C patent/HUS2100025I1/hu unknown
- 2021-07-06 NO NO2021027C patent/NO2021027I1/no unknown
- 2021-07-12 FR FR21C1030C patent/FR21C1030I2/fr active Active
- 2021-07-13 LT LTPA2021515C patent/LTC3101032I2/lt unknown
- 2021-07-13 JP JP2021115436A patent/JP7146031B2/ja active Active
- 2021-07-16 NL NL301117C patent/NL301117I2/nl unknown
- 2021-11-30 CY CY20211101037T patent/CY1124774T1/el unknown
-
2022
- 2022-06-02 AU AU2022203818A patent/AU2022203818A1/en active Pending
- 2022-09-20 JP JP2022149242A patent/JP7467557B2/ja active Active
-
2023
- 2023-09-12 US US18/367,446 patent/US20240026030A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2017095457A5 (ja) | ||
HRP20210593T1 (hr) | Anti-her3 antitijelo-lijek konjugat | |
HRP20211164T1 (hr) | Derivati hemiasterlina za konjugaciju i terapiju | |
JP2015508074A5 (ja) | ||
JP2019502746A5 (ja) | ||
AU2020263231A1 (en) | Camptothecin derivatives | |
IL270852A (en) | Molecules that bind at the site of egfr and c – met - fibronectin type iii | |
IL266563B (en) | Heterocyclic compounds used as pdk1 inhibitors | |
HRP20211710T1 (hr) | Konjugacija specifična za mjesto spajanja lijekova za povezivanje s protutijelima i konjugati protutijela u lijeku koji nastaje kao rezultat | |
JP2021503450A5 (ja) | ||
JP2018508572A5 (ja) | ||
JP2020536066A5 (ja) | ||
JP2019512478A5 (ja) | ||
JP2017536340A5 (ja) | ||
JP2018507197A5 (ja) | ||
JP2018516966A5 (ja) | ||
JP2018537975A5 (ja) | ||
FI3345613T3 (fi) | Koostumus käytettäväksi syövän tai angiogeneesiin liittyvän sairauden hoidossa käsittäen tuumoriin penetroituvan peptidin ja VEGF-estäjän fuusioproteiinin | |
JP2017533266A5 (ja) | ||
JP2015524399A5 (ja) | ||
JP2011505146A5 (ja) | ||
RU2016117810A (ru) | Конъюгаты белок-полимер-лекарственное средство | |
EA200970700A1 (ru) | Ингибиторы киназы, пригодные для лечения миелопролиферативных заболеваний и других пролиферативных заболеваний | |
JP2020502271A5 (ja) | ||
JP2017530184A5 (ja) |